Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of obesity / overweight for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s obesity / overweight forecast will answer the following questions:

  • Of all people with obesity / overweight, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity / overweight over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts 11 obesity / overweight patient populations, as follows:

  • Diagnosed prevalent cases of obesity / overweight.
  • Undiagnosed prevalent cases of obesity / overweight.
  • Total prevalent cases of obesity.
  • Total prevalent cases of class I obesity.
  • Total prevalent cases of class II obesity.
  • Total prevalent cases of class III obesity.
  • Total prevalent cases of overweight.
  • Total obesity prevalent cases after effective usage of GLP-1 RAs.
  • Drug-treatable prevalent cases of overweight.
  • Diagnosed drug-treated prevalent cases of obesity.
  • Diagnosed non-drug-treated prevalent cases of obesity.
  • … and more (details available on request).

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…
Report
Primary Biliary Cholangitis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease, characterized by inflammation and progressive damage leading to destruction of interlobular bile ducts, followed by cholestasis…
Report
Type 1 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment options for type 1 diabetes (T1D) patients are limited; insulins, pramlintide (in the United States), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors (only in Japan) are the…
Report
Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…